ĀÜĄņĀŅĀ×

Dr. Hazlehurst is President and co-founder of Modulation Therapeutics Incorporated. Her research interests are focused on the identification of novel targets which mediate survival and tumor progression in the context of the bone marrow microenvironment. More recently she has focused her laboratory on developing strategies directed at targeting cell adhesion molecules that contribute to homing and drug resistance. She is co-inventor of MTI-101 and a method of use to treat cancer for HYD1. She has over 15 years of experience in defining mechanism of action and pre-clinical development of novel oncology agents.